On the other hand, other groups observed an opposite trend; it was reported that KRAS and TP53 mutations could serve as a positive predictive factor in guiding immunotherapy in lung adenocarcinoma, boosting PD-L1 expression and increasing tumor immunogenicity [24]. The gene discussed is KRAS; the disease is lung adenocarcinoma.